.png)
.png)
Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines
OXFORD, UK – 19 October 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax® enabled pandemic flu vaccine.
ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine.
Under NIAID’s suite of preclinical services, NIAID-funded contractors will test the ImplaVax® formulation in animal model challenge studies against flu viruses. The study will generate additional key efficacy data to complement the excellent thermal stability, efficacy and needle-free delivery data already shown in support of future clinical development.
The study is scheduled to begin in Q4 2021.
David Hipkiss, Enesi Pharma CEO, commented: “ImplaVax® can reduce wastage, eliminate the need for cold-chain logistics, and allow for easier administration of vaccines – representing a potential paradigm shift in the deployment and reach of mass-immunisation programmes like those regularly undertaken for influenza. We are excited to expand upon our successful work with BARDA and with the assistance of NIAID advance our understanding and future use of ImplaVax® in this critical area of international importance.”
NIAID is continually preparing for pandemic influenza, including the potential for a wider spread of emerging strains of avian influenza, such as the H7N9 virus. NIAID and its funded researchers are conducting preclinical and clinical studies on various investigational pandemic flu vaccines.
The study will utilize NIAID’s preclinical services program, which supports NIAID’s strategic plan to develop flu vaccines capable of providing durable protection against multiple influenza strains.
ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats.
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine.
Under NIAID’s suite of preclinical services, NIAID-funded contractors will test the ImplaVax® formulation in animal model challenge studies against flu viruses. The study will generate additional key efficacy data to complement the excellent thermal stability, efficacy and needle-free delivery data already shown in support of future clinical development.
The study is scheduled to begin in Q4 2021.
David Hipkiss, Enesi Pharma CEO, commented: “ImplaVax® can reduce wastage, eliminate the need for cold-chain logistics, and allow for easier administration of vaccines – representing a potential paradigm shift in the deployment and reach of mass-immunisation programmes like those regularly undertaken for influenza. We are excited to expand upon our successful work with BARDA and with the assistance of NIAID advance our understanding and future use of ImplaVax® in this critical area of international importance.”
NIAID is continually preparing for pandemic influenza, including the potential for a wider spread of emerging strains of avian influenza, such as the H7N9 virus. NIAID and its funded researchers are conducting preclinical and clinical studies on various investigational pandemic flu vaccines.
The study will utilize NIAID’s preclinical services program, which supports NIAID’s strategic plan to develop flu vaccines capable of providing durable protection against multiple influenza strains.